Global Antiviral Drugs Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

Pfizer's COVID antiviral Paxlovid gains US approval in 2023

• Antiviral medications are those created specifically to target and prevent the spread and replication of viruses within the human body. They are essential for managing and treating viral infections. These medications function by either directly attacking the virus or preventing it from proliferating and infecting healthy cells. Antiviral medications are essential tools for both preventing and treating viral infections. They assist in symptom relief, lessen the severity and length of illnesses, and enhance patient outcomes. Global efforts to combat viral diseases are aided by ongoing research and development in the field of antiviral therapy, which is expanding the options for effective treatment against various viral infections.
• The demand for antiviral medications is anticipated to rise due to the rising prevalence of viral infections like HIV, Herpes, Influenza, and others over the forecast period. Global demand for antiviral medications has significantly increased as a result of the COVID-19 pandemic. The need for broad-spectrum antiviral medications has increased due to the management of novel coronaviruses. For the treatment of COVID-19, remdesivir, favipiravir, oseltamivir, and other combination medications are frequently prescribed. Additionally, governments are providing pharmaceutical companies with more funding to create cutting-edge treatments for COVID-19. Additionally, several pharmaceutical firms are concentrating on developing new drugs to offer patients better patient outcomes and more effective treatments.
• An increase in the reported rate of viral disorders is driving the global market share for anti-viral medications. The market for antiviral drugs is also anticipated to be driven by an increase in R&D activities and the expansion of more recent and updated information, such as vaccinations and combined therapy. Time is needed and the market revenue and profit are constrained in creating a safe, effective, and targeted antiviral. Potential viral pandemics highlight the need for rapid, widespread deployment of broad-spectrum antiviral drugs, like direct-acting antivirals, to stop viral spread until adequate vaccines are developed. The market for antiviral medications is also anticipated to be constrained by growing knowledge of infection prevention strategies and vaccination accessibility.
• Numerous novel drugs are anticipated to be developed during the forecast period as a result of increased partnerships for antiviral drug development and manufacturing. The market's top rivals are working together to develop cutting-edge therapies that will lessen the virus strain that antiviral medications can treat. The market for antiviral medications is expanding as a result of developments in science and technology. A better understanding of viral replication mechanisms has been made possible by advances in genomics, proteomics, and molecular biology, opening up new avenues for the development of therapeutic interventions. As a result, more potent and specific antiviral therapies have been created.
• The global market for antiviral medications has bright future prospects. There is a lot of potential in the ongoing developments in antiviral drug research and development, including investigating novel drug targets and creating broad-spectrum antivirals. Additionally, developing novel technologies like CRISPR-based therapeutics and RNA interference (RNAi) opens up new possibilities for discovering antiviral drugs. The successful development and widespread use of COVID-19 vaccines is further evidence of the growing emphasis on viral disease prevention through vaccination, which is likely to affect the demand for antiviral medications. Antivirals can be used as additional therapies or as preventative measures in high-risk populations, enhancing the function of vaccines in the management of disease.

Market Segmentations

• The Global Antiviral Drugs Market is segmented based on Drug Type, Disease, and Geography.
• By Drug Type, the market is classified into DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, and Others.
• The reverse transcriptase inhibitors segment dominated the market for antiviral medications. Over the forecast period, the segment is expected to continue to rule. Since reverse transcriptase inhibitors are primarily used to treat HIV infection and have a high level of effectiveness against viral infections, the high share of these medications can be attributed to the rising rates of HIV diagnosis and treatment. Additionally, the development of reverse transcriptase inhibitors will increase the demand for these medications in the upcoming years. Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) are drugs in this class.
• The market for protease inhibitors, which accounted for the second-highest revenue share, is projected to fastest growth during the forecast period. Reduced R&D activities for the creation of protease inhibitors and increased vaccination against viral infections are to blame for the segment growth's decline.
• By Disease, the market is classified into HIV/Aids, Hepatitis (B & C), Herpes, Influenza, Pneumonia, and Others.
• The HIV segment dominated the market. Over the forecast period, the segment is anticipated to grow at the fastest rate. According to estimates, the market will expand at a faster rate due to factors like the high prevalence of HIV infection, the high treatment rate, the availability of branded drugs, and government initiatives to raise the treatment rate.
• The second-largest revenue share belonged to the hepatitis segment. The growth is being negatively impacted by increasing hepatitis A and B vaccination rates. Additionally, the COVID-19 pandemic outbreak has significantly boosted the others segment's growth.
• By Geography, the market is classified into the Americas, Europe, Middle-East & Africa, and Asia-Pacific.
• Americas dominated the market and generated the largest portion of revenue. The loss of brand-name drugs' market exclusivity, rising rates of vaccination against viral infections, and government initiatives to lower the incidence of viral infections can all be blamed for the market decline. For instance, the U.S. government is taking several actions, such as funding programs for infectious diseases and encouraging research and development of novel treatments for viral infections. The market for antiviral medications is anticipated to expand at the fastest rate in Asia Pacific during the forecast period.

Recent Development

• Aurobindo Pharma Limited launched the anti-viral drug molnupiravir under the brand name Molnaflu for COVID-19 treatment in India. This strengthened the company’s product portfolio, thereby creating revenue growth opportunities. - January 2022
• Lupin launched the anti-viral drug Molnupiravir in India under the brand name Molnulup to treat adults suffering from COVID-19 in the country. - January 2022
• ENTOD Pharmaceuticals launched MOLENTOD in India. The product was made available at affordable prices at retail chemists, pharmacy chains, hospitals, and online stores. - January 2022
• Scripps Research, a non-profit research and technology and drug discovery organization, and AbbVie Inc. established a strategic collaboration to investigate novel, immediate antiviral treatments for COVID-19. - March 2022

Company Profiles

Countries Studied

• America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
• Europe (Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Luxemburg, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
• Middle-East and Africa (Egypt, Israel, Qatar, Nigeria, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
• Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

Ansoff Analysis

• The report presents a detailed Ansoff matrix analysis for the Global Antiviral Drugs Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development, and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
• The publisher analyses the Global Antiviral Drugs Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
• Based on the SWOT analysis conducted on the industry and industry players, the publisher has devised suitable strategies for market growth.

Why buy this report?

• The report offers a comprehensive evaluation of the Global Antiviral Drugs Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
• The research report also provides a detailed market size analysis and projections in volume and value terms. The projections are calculated using verified research methodologies.
• Excel data sheet for the market size will also be provided with the report.
• The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
• The report includes an in-depth market analysis using Porter’s 5 forces model, PESTLE Analysis, and the Ansoff Matrix. In addition, the impact of COVID-19 on the market is also featured in the report.
• The report includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
• The report includes Self-Assessment Form, which helps customers evaluate their position in the market compared to their competitors
• The report offers customized research - tailored uniquely to our customers with a quick turnaround time. We offer a 15% customization option at no extra charge to all our clients for any of our syndicated reports.

Report Highlights:

• A complete analysis of the market, including the parent industry
• Important market dynamics and trends
• Impact Analysis - a comprehensive assessment to confront risk and make strategic & operational decisions to counter the changes in the market environment.
• Market segmentation
• Competitive Analysis: Comparative analysis of competitor
• Historical, current, and projected size of the market based on value and volume
• Market size of the US states
• Market shares and strategies of key players
• Recommendations to companies for strengthening their foothold in the market